Cimon Medical

What Cimon Medical does

Cimon Medical, headquartered in Trondheim, Norway, develops and manufactures Doppler ultrasound technology for continuous, non-invasive blood flow monitoring in healthcare facilities. The company's platform is built on a patented method architecture originating from research at NTNU and St. Olavs University Hospital, co-invented by Professor Hans Torp and Pediatric Cardiologist Siri Ann Nyrnes. The technology measures blood flow velocity within a region rather than attempting absolute measurement in a single vessel, circumventing a limitation that had previously prevented continuous clinical adoption.

The company operates two core products: NeoDoppler, a hemodynamic monitoring system providing direct continuous non-invasive cerebral blood flow measurement in infants via a disposable ultrasound probe applied over the anterior fontanelle (CE marked and MDR certified at TÜV SÜD, commercially launched Q4 2022); and ResQDoppler, a carotid Doppler monitoring solution for continuous blood flow assessment during CPR that can detect return of spontaneous circulation and is positioned for both standalone hospital/EMS sales and OEM integration inside third-party defibrillators. ResQDoppler incorporates AI-driven anomaly detection on Doppler signals and obtained first human clinical data in 2023.

Cimon Medical makes money primarily through hardware sales of NeoDoppler systems and recurring single-use disposable probes, supplemented by ResQDoppler standalone device sales and a planned OEM/licensing revenue stream via defibrillator integration. The company sells directly to large European hospitals while actively expanding a distributor network across Europe, and engages in extensive clinical validation and peer-reviewed publication activity as a core demand-generation mechanism for evidence-driven adoption in NICUs and emergency departments.

Name

Cimon Medical

Legal name

Cimon Medical

Website

https://cimonmedical.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Cimon Medical develops and manufactures Doppler ultrasound technology for continuous, non-invasive blood flow monitoring, serving European hospitals with its NeoDoppler (neonatal cerebral blood flow) and ResQDoppler (carotid monitoring during CPR) products.

Ownership category

akta.pro rank

Product category

Ultrasound Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Ultrasound & Echography Systems (HLAHABAD)

akta.pro secondary industry

Maternal, Fetal & Neonatal Monitoring (CTG, Infant Wearables) (HLAHACAF)

Keywords

• Doppler ultrasound monitoring
• Neonatal blood flow
• Cerebral perfusion monitoring
• Cardiac arrest monitoring
• Medical device manufacturing

Headquarters

HQ city

Trondheim

HQ country

Norway

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D

Revenue model

1. NeoDoppler System Sales: Sales of the NeoDoppler Doppler ultrasound system for cerebral blood flow monitoring in infants, including the display unit and disposable probes for single-patient use.
2. Disposable Probes: Single-use disposable ultrasound probes for each patient examination, creating recurring revenue from consumables.
3. ResQDoppler OEM Components: ResQDoppler technology sold as OEM component embedded inside third-party defibrillators, creating licensing/integration revenue stream.
4. ResQDoppler Standalone Device: Standalone ResQDoppler device for emergency medical services and hospitals performing cardiac arrest resuscitation.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Cimon Medical develops and manufactures novel Doppler ultrasound systems for continuous, non-invasive blood flow monitoring in healthcare facilities. Its two commercial products are NeoDoppler, a cerebral blood flow monitor for infants placed over the anterior fontanelle, and ResQDoppler, a carotid artery monitor for use during CPR that can be sold standalone or embedded as an OEM module inside defibrillators. Both products leverage a patented Doppler ultrasound platform originating from research at NTNU and St. Olavs University Hospital.

Product overview

Cimon Medical develops and manufactures Doppler ultrasound technology for healthcare facilities, consisting of two core monitoring products. NeoDoppler® provides non-invasive continuous cerebral blood flow monitoring for infants, particularly preterm neonates at risk of brain damage. ResQDoppler® measures continuous blood flow in the carotid artery during CPR to detect return of spontaneous circulation and optimize compression positioning. Both products share the company's core Doppler ultrasound technology platform, with NeoDoppler focused on neonatal intensive care and ResQDoppler on emergency cardiac arrest response.

Differentiator

Problem solved

Functional benefit

Brands

• NeoDoppler: Doppler ultrasound system for non-invasive continuous blood flow monitoring for infants, specifically designed for cerebral blood flow monitoring in preterm and newborn infants.
• ResQDoppler

Products and services

• NeoDoppler Doppler ultrasound hemodynamic monitoring system that provides the first direct, continuous, non-invasive measurement of cerebral blood flow in preterm and newborn infants. It consists of a standalone display unit connecting to an ultrasound scanner with a disposable single-use probe attached over the anterior fontanelle, intended for use in neonatal intensive care units (NICUs), during surgery, and during resuscitation.
• ResQDoppler Doppler ultrasound device for continuous, non-invasive monitoring of carotid artery blood flow during cardiopulmonary resuscitation (CPR). Uses an innovative ultrasound patch for rapid application, allows monitoring during chest compressions without interruption, and employs AI to detect return of spontaneous circulation (ROSC) and ineffective compressions. Designed for emergency medical services, ambulances, and hospital emergency departments.

Quantifiable outcome

• Less than 10% survive sudden cardiac arrest outside of hospital with current methods
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

Five partnerships are on record, tiered supporting and core.

• Children's Hospital of PhiladelphiasupportingStrategic or Co-development Partner · 1 January 2024Collaboration on animal data correlating cerebral flow and carotid flow during ResQDoppler research, demonstrating international research partnerships for clinical validation.
• Selected Manufacturing PartnerssupportingTechnology or Integration · 1 January 2020Industrialization process initiated in 2020 with selected manufacturing partners for production of NeoDoppler system components.
• Norwegian University of Science and Technology (NTNU)coreStrategic or Co-development Partner · 1 January 2015Technology originated from the world-renowned ultrasound environment at NTNU in Trondheim, Norway. NTNU's Department of Circulation and Imaging developed Doppler ultrasound for clinical use from 1976-2015. Professor Hans Torp, a driving force in the local ultrasound community, developed the idea and concept for Cimon technology from 2015-2017. NTNU has approximately 5360 academic staff and 40,000 students with annual budget of approx. 9 billion Norwegian kroner.
• St. Olavs University HospitalcoreStrategic or Co-development Partner · 1 January 2015Clinical partner where pilot and clinical studies with prototypes were initiated from 2017-2019 at St. Olavs and Oslo University Hospital. St. Olavs Hospital collaborates closely with NTNU on education and has responsibility for sharing knowledge and supporting professional development in central Norway.
• NTNU Technology Transfer AScoreStrategic or Co-development Partner · 1 January 2015Technology transfer organization that works to create value from research-based ideas from NTNU and The Central Norway Regional Health Authority. Goal is to create benefit to society through new products, services, industries, and jobs. Cimon Medical was formed as a spin-off from this technology transfer process.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Natus Medical: Natus Medical is a leader in neonatal and neurology medical devices, including NICU monitoring solutions. Its installed base and sales infrastructure in neonatal intensive care make it the closest direct competitor to NeoDoppler in the NICU cerebral monitoring segment.
• Nonin Medical: Nonin Medical specializes in pulse oximetry and regional oximetry sensors (Equanox) used in neonatal and critical care monitoring. It addresses similar cerebral/peripheral oxygenation monitoring use cases as NeoDoppler, though using a different sensing technology.
• Deltex Medical: Deltex Medical develops Doppler-based hemodynamic monitoring technology (CardioQ and TrueVue systems) for non-invasive cardiac output measurement. It is a direct competitor in Doppler-based continuous blood flow monitoring, addressing overlapping clinical use cases in perioperative and critical care settings.
• CNSystems Medizintechnik: CNSystems manufactures non-invasive hemodynamic monitoring devices (CNAP, Task Force Monitor) using finger cuff and other technologies. It competes with Cimon in continuous non-invasive cardiovascular monitoring in operating rooms and ICUs.

Broad incumbents

• ZOLL Medical (Asahi Kasei): ZOLL manufactures defibrillators and CPR feedback devices (R Series, X Series) used by EMS and hospitals. As a leading defibrillator OEM, it is both a potential ResQDoppler integration partner and a competitor with its own CPR quality monitoring technology.
• Masimo: Masimo is a global leader in patient monitoring technology, including pulse oximetry and rainbow SET sensors used in NICUs. While its core technology differs, Masimo competes for the same NICU monitoring budget and bedside workflow as NeoDoppler.
• Philips Healthcare: Philips offers a broad portfolio of patient monitoring, neonatal care (IntelliVue, Avalon), and defibrillators (HeartStart). It competes with both NeoDoppler in NICUs and ResQDoppler in CPR/defibrillation settings through its established global hospital channel.
• Medtronic: Medtronic offers a broad portfolio including patient monitoring (INVOS cerebral oximeter for NICUs) and defibrillators (Lifepak). INVOS uses NIRS in the same NICU clinical decision-making workflow that NeoDoppler targets.
• Edwards Lifesciences: Edwards Lifesciences is the dominant player in hemodynamic monitoring with the FloTrac, ClearSight, and Swan-Ganz systems used in operating rooms and ICUs. It competes with Cimon for the same continuous hemodynamic monitoring budget and clinical decision-making workflow.
• Stryker (Physio-Control): Stryker's Physio-Control division manufactures LIFEPAK defibrillators and CPR feedback tools used by EMS globally. As with ZOLL, it represents both a potential ResQDoppler OEM partner and a competitor with established CPR monitoring capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/cimonmedical

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cimon Medical